Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0677-2025

DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimens Recall

DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimens

FDA recall Class II

Ongoing

FDA lists this Class II recall for DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimens. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0677-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Nov 7, 2024
FDA report date
Dec 18, 2024
Quantity in commerce
21905 units
Distribution
See key details
FDA cause
Process control

What is being recalled?

DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimens

Affected model & UDI checker

Search the exact identifiers published for Z-0677-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
319060DiaSorin LIAISON Q.S.E.T. Device Plus, REF 319060; intended for use in the preparation of human stool specimensCheck source noticeNot specified
FDA code information

UDI/DI 80567713190605F, Lot Numbers: 225084, 232094, 234114, 259144, 221214, 252244, 230094, 224124, 205144, 228174, 228224, 223274, 219104, 217134, 233154, 236174, 224244, 232294, 229224, 251234, 221294, 210204, 223244, 222314

View the original FDA recall notice

Why was this product recalled?

Customer complaints were received alleging leaking devices and insufficient buffer volume. Diasorin's internal investigation determined that 0.14% of the LIAISON Q.S.E.T. Device Plus in the lots identified have loose clear caps, which may allow buffer to leak from the tube. A stool sample prepared with less than the correct amount of buffer may result an incorrectly high patient result.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did DiaSorin, Inc. take?

DiaSorn issued an Urgent Field Safety Notice - Medical Device Recall notice to its consignees on 11/07/2024 via email. The notice explained the issue with the product, risk to health, and requested the following: "Ac xons to be taken by the Customer/User " No need to review past patient results. " Devices should be inspected for loose clear caps prior to use. The user should confirm that the clear cap is tight by grasping the cap and twisting. If the cap is loose, the device should be discarded. Do not attempt to use the device as the loose clear cap may have allowed buffer to leak, causing insufficient buffer volume. " Customers should forward this communication to required individuals within the organization or to any organization where the potentially affected devices have been distributed. " Diasorin will replace any tubes found with loose clear caps. Contact Diasorin Product Support for replacement product." For questions or concerns, contact: Diasorin Product Support: 1-800-328-1482 Select Option 1 (U.S. and Canada); 1-651-351-5888 (Fax); productsupport@diasorin.com

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology